Real-world effectiveness and safety of pembrolizumab monotherapy in non-small-cell lung carcinoma with brain metastases
Farmacia Hospitalaria · 2026-09
DOI: 10.1016/j.farma.2026.07.009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Farmacia Hospitalaria, 2026-09. Verfasst von Juan Carlos Del Río-Valencia und 4 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Farmacia Hospitalaria, Hospital Regional Universitario de Málaga, Málaga, Spain. Electronic address: juancardelrio@telefonica.net. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
OBJECTIVE: The objective of this study was to evaluate the effectiveness and safety of pembrolizumab as monotherapy in patients with Non-Small-Cell Lung Cancer and brain metastases in Real-World clinical practice at Tertiary care. MATERIAL AND METHODS: A retrospective observational study was conducted at a tertiary hospital in Spain between August 2017 and March 2023. Adult patients with stage IV non-small-cell lung carcinoma and radiologically confirmed brain metastases who received pembrolizumab monotherapy were included. Progression-free survival, overall survival, objective response rate and treatment-related adverse events were analyzed. RESULTS: Among 172 patients treated with pembrolizumab, 45 had brain metastases and 25 received monotherapy. Median progression-free survival was 3 months (95% confidence interval: 2.02-3.97), and median overall survival was 6 months (95% confidence interval: 4.37-7.62). The objective response rate was 24%, and the disease control rate was 40%. Treatment-related toxicity of any grade was reported in 64% of patients, with no unexpected safety signals observed. CONCLUSIONS: Pembrolizumab monotherapy showed clinical activity and an acceptable safety profile in patients with non-small-cell lung carcinoma and brain metastases treated in routine practice. Larger prospective studies are needed to optimize patient selection in this setting.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Servicio de Farmacia Hospitalaria, Hospital Regional Universitario de Málaga, Málaga, Spain. Electronic address: juancardelrio@telefonica.net.
- Servicio de Farmacia Hospitalaria, Hospital Regional Universitario de Málaga, Málaga, Spain; Programa de Doctorado en Biomedicina, Investigación Traslacional y Nuevas Tecnologías en Salud, Universidad de Málaga, Málaga,…
- Servicio de Farmacia Hospitalaria, Hospital Regional Universitario de Málaga, Málaga, Spain.
- Servicio de Oncología Médica, Gibraltar Health Authority, Gibraltar.
Zitieren
APA
Del Río-Valencia, J. C., Tamayo-Bermejo, R., Paradas-Palomo, J. D., Mora-Rodríguez, B., & López-Escola, C. (2026). Real-world effectiveness and safety of pembrolizumab monotherapy in non-small-cell lung carcinoma with brain metastases. Farmacia Hospitalaria. https://doi.org/10.1016/j.farma.2026.07.009
Vancouver
Del Río-Valencia JC, Tamayo-Bermejo R, Paradas-Palomo JD, Mora-Rodríguez B, López-Escola C. Real-world effectiveness and safety of pembrolizumab monotherapy in non-small-cell lung carcinoma with brain metastases. Farmacia Hospitalaria. 2026. doi:10.1016/j.farma.2026.07.009
BibTeX
@article{DelRoValencia2026,
author = {Del Río-Valencia, Juan Carlos and Tamayo-Bermejo, Rocío and Paradas-Palomo, Juan Diego and Mora-Rodríguez, Beatriz and López-Escola, Cristina},
title = {Real-world effectiveness and safety of pembrolizumab monotherapy in non-small-cell lung carcinoma with brain metastases},
journal = {Farmacia Hospitalaria},
year = {2026},
doi = {10.1016/j.farma.2026.07.009}
}
EUVIMED